Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phenylpropanolamine + chlorpheniramine
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Phenylpropanolamine + chlorpheniramine is a fixed-dose combination pharmaceutical product manufactured by Chemidrug Industries in Nepal. It combines phenylpropanolamine, a sympathomimetic amine that functions as a nasal decongestant, with chlorpheniramine, a first-generation alkylamine antihistamine. Phenylpropanolamine acts as an agonist at alpha-adrenergic receptors, leading to vasoconstriction of the respiratory tract mucosa and a reduction in nasal congestion. Chlorpheniramine serves as a potent H1 receptor antagonist, blocking the effects of histamine to alleviate symptoms such as sneezing, rhinorrhea, and itchy eyes. This combination is indicated for the symptomatic relief of the common cold, allergic rhinitis, and other upper respiratory allergies. While phenylpropanolamine has been withdrawn from many Western markets due to safety concerns, it remains available in certain regions as a generic medication.
- Other names
- chlorpheniramine + phenylpropanolamine
02
Targets
β-AR (Beta-adrenergic receptor family)ADRB1 (β1)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)DRD1 (Dopamine D1 Receptor)ADRA2A (α2A)
Beyond the preview
Go deeper on phenylpropanolamine + chlorpheniramine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phenylpropanolamine + chlorpheniramine.